help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
The Oncologist, Vol. 4, No. 4, viii, August 1999
© 1999 AlphaMed Press

Editorial

Promising New Drugs and Combinations...Fulfilling Our Pledge

We are fortunate, as physicians and clinical researchers, to live in a time of unprecedented expansion of treatment approaches. Much of this change is due to the application of new knowledge regarding the causes of malignant transformation and progression, and the pace of research and its application is likely to quicken. The pace of change is exemplified by the number and variety of new drugs that will transform treatment of cancer in the next few years: antibodies for breast cancer and lymphoma, differentiating agents for acute promyelocytic leukemia, molecularly targeted agents for chronic myelocytic leukemia, antiangiogenic drugs, antimetastatic agents, and new natural products with unique mechanisms of action. Some are already approved and in routine use, while others are progressing rapidly through the pre-approval process. All of this change presents a challenge to the practicing oncologist who must understand the biology, pharmacology, and clinical uses of the new drugs. What are the advantages, limitations, risks, and benefits of the drugs, how do they interact with other drugs and with irradiation, and how are they likely to be used in the future?

To provide timely access to this information, The Oncologist has asked its board of editors to develop a new section of the Journal that will be devoted to Promising New Drugs and Combinations. Two experienced and highly respected clinical researchers, Frank Balis, Chief of the Pharmacology and Experimental Section in the Pediatrics Branch at the National Cancer Institute, and Michael Hawkins, Associate Director at the Washington Hospital Center Cancer Institute, have agreed to edit and oversee this section of the journal and will make sure that our readership has essential information on new drugs as they approach marketing status. Please let us know if we are providing useful and timely information. We value your suggestions for making The Oncologist the most relevant of all the journals you read.Please let us know if we are providing useful and timely information...for making The Oncologist the most relevant of all the journals you read.




View larger version (138K):
[in this window]
[in a new window]
  		Bruce A. Chabner, MD Editor-in-Chief Chief Medical Officer Dana-Farber/Partners Cancer Care Massachusetts General Hospital

 




This Article
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS